ResMed Business Model Canvas
Unlock the strategic Business Model Canvas for a leading sleep-tech innovator
Unlock the full strategic blueprint behind ResMed’s business model with our in-depth Business Model Canvas—three to five actionable sentences show how ResMed creates value, scales distribution, and monetizes clinical innovation. Ideal for investors, consultants, and founders, this downloadable Word/Excel file gives a section-by-section breakdown and ready-to-use slides for benchmarking or strategy work—purchase the full canvas to dive deeper.
Partnerships
Hospitals and sleep clinics
Clinical providers conduct diagnostics, prescribe therapy, and drive device adoption, linking hospital pathways to home care; obstructive sleep apnea affects an estimated 936 million adults worldwide. Partnerships ensure seamless patient referrals and titration workflows, reducing friction across care transitions. Co-development of protocols with hospitals and sleep clinics elevates clinical outcomes and adherence; ResMed supports over 8 million cloud-connected devices globally, enabling data-driven follow-up.
Durable medical equipment (DME) distributors
DME distributors manage last-mile delivery, device setup, and patient training for home sleep and ventilation, reducing onboarding times and readmissions. They handle mask and supplies replenishment, sustaining recurring consumables revenue—ResMed reported approximately $4.9B revenue in FY2024 with consumables/services ~35% of sales. Joint programs with DMEs raise adherence and tighten resupply cadence, improving lifetime customer value.
Payers and health systems
Payers and integrated delivery networks control CPAP and ventilator coverage, prior authorizations and reimbursement levels that shape ResMed market access. Value-based contracts increasingly tie payments to adherence and outcomes, with studies reporting up to 30% fewer hospitalizations when PAP therapy is optimized. Shared device and adherence data have supported cost-effectiveness evidence used in payer negotiations and formulary decisions.
Component suppliers and OEMs
- High-quality components
- Supply reliability & cost stability
- Co-innovation: quieter, smaller, efficient
Software and telehealth partners
- Integrations: EHRs, telemedicine, remote monitoring
- Scale: ~15M+ cloud devices (2024)
- Financial context: ~$4.8B FY2024 revenue
- APIs: clinician workflows, patient self-management
- Outcomes: enhanced data-driven care pathways
Partnerships drive adherence, consumables ~35%, 15M devices
Key partnerships with hospitals, DMEs, payers, suppliers and telehealth platforms enable referrals, last‑mile setup, reimbursement access, component supply and remote care integration; ResMed reported ~$4.8B FY2024 revenue and ~15M cloud‑enabled devices in 2024. These alliances drive adherence, recurring consumables (~35% of sales) and value‑based contracts that lower hospitalizations.
| Partner | Role | 2024 metric |
|---|---|---|
| Hospitals/Clinics | Referrals, protocols | 15M cloud devices |
| DMEs | Delivery, training, resupply | Consumables ~35% rev |
| Payers | Coverage, value contracts | ↓ hospitalizations up to 30% |
| Suppliers | Motors, sensors | Supply stability for $4.8B rev |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for ResMed outlining nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure—reflecting its connected sleep and respiratory care strategy, competitive strengths, risks, and investor-ready insights.
Customizable Excel Spreadsheet
Condenses ResMed’s business model into a one-page snapshot showing how its connected CPAP devices, cloud-based monitoring and integrated services relieve clinical and operational pain points—improving patient adherence, reducing hospital readmissions and lowering provider workload. Shareable and editable for team collaboration or quick executive summaries.
Activities
Medical device R&D
ResMed’s medical device R&D designs and tests CPAPs, masks, ventilators and diagnostics, iterating on materials and airflow for comfort and noise reduction to boost adherence. R&D emphasizes smart features—remote monitoring and algorithmic therapy adjustments—to raise nightly use rates. Clinical studies in 2024 continued to validate safety and efficacy, supporting regulatory approvals; ResMed invested about $383 million in R&D in FY2024.
Regulatory and quality management
ResMed maintains compliance with FDA, CE and global standards across 140+ countries, underpinning a FY2024 revenue base of roughly $4.6B. Robust post-market surveillance and CAPA processes track safety signals and drive corrective actions. Comprehensive documentation and traceability support audits, regulatory submissions and market access decisions worldwide.
Manufacturing and supply chain
Scale production with strict quality controls to support ResMed’s global footprint after FY2024 revenue of $4.92 billion. Manufacturing relies on multi-sourced components and inventory buffering to maintain device availability across more than 120 countries. Logistics networks are optimized for rapid global distribution and service-level targets. Continuous quality audits sustain regulatory compliance and yield targets.
Cloud software development
ResMed's cloud software development builds remote monitoring, analytics and patient apps—supporting over 11 million connected devices and contributing to FY2024 revenue of $4.6B; it enforces security, privacy and FHIR interoperability; delivers OTA updates that boost adherence and cut clinic workflow time by ~20%.
- Remote monitoring: real-time telemetry
- Security: HIPAA, FHIR-compatible
- Updates: higher adherence, -20% clinic time
Commercial and clinical education
- Train clinicians, DMEs, patients on setup/best practices
- Adherence programs & outreach to improve therapy use
- Reimbursement support & health-economic evidence
R&D $383M: CPAPs, masks, ventilators & cloud; ~11M devices, >20M patients
ResMed focuses R&D on CPAPs, masks, ventilators and cloud software, investing $383M in FY2024 to improve comfort, algorithms and remote monitoring for ~11M connected devices. Manufacturing and QA scale to supply >120 countries supporting FY2024 revenues of $4.92B. Clinical, reimbursement and adherence programs served >20M patients in 2024.
| Metric | 2024 |
|---|---|
| R&D spend | $383M |
| Connected devices | ~11M |
| Patients served | >20M |
| Revenue (FY) | $4.92B |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual ResMed Business Model Canvas you'll receive after purchase. It's not a mockup—it's the same editable, ready-to-use file, formatted for presentation and analysis in Word and Excel. Purchase unlocks the complete document with all content included—no surprises, ready to edit and share.
Unlock the strategic Business Model Canvas for a leading sleep-tech innovator
Unlock the full strategic blueprint behind ResMed’s business model with our in-depth Business Model Canvas—three to five actionable sentences show how ResMed creates value, scales distribution, and monetizes clinical innovation. Ideal for investors, consultants, and founders, this downloadable Word/Excel file gives a section-by-section breakdown and ready-to-use slides for benchmarking or strategy work—purchase the full canvas to dive deeper.
Partnerships
Hospitals and sleep clinics
Clinical providers conduct diagnostics, prescribe therapy, and drive device adoption, linking hospital pathways to home care; obstructive sleep apnea affects an estimated 936 million adults worldwide. Partnerships ensure seamless patient referrals and titration workflows, reducing friction across care transitions. Co-development of protocols with hospitals and sleep clinics elevates clinical outcomes and adherence; ResMed supports over 8 million cloud-connected devices globally, enabling data-driven follow-up.
Durable medical equipment (DME) distributors
DME distributors manage last-mile delivery, device setup, and patient training for home sleep and ventilation, reducing onboarding times and readmissions. They handle mask and supplies replenishment, sustaining recurring consumables revenue—ResMed reported approximately $4.9B revenue in FY2024 with consumables/services ~35% of sales. Joint programs with DMEs raise adherence and tighten resupply cadence, improving lifetime customer value.
Payers and health systems
Payers and integrated delivery networks control CPAP and ventilator coverage, prior authorizations and reimbursement levels that shape ResMed market access. Value-based contracts increasingly tie payments to adherence and outcomes, with studies reporting up to 30% fewer hospitalizations when PAP therapy is optimized. Shared device and adherence data have supported cost-effectiveness evidence used in payer negotiations and formulary decisions.
Component suppliers and OEMs
- High-quality components
- Supply reliability & cost stability
- Co-innovation: quieter, smaller, efficient
Software and telehealth partners
- Integrations: EHRs, telemedicine, remote monitoring
- Scale: ~15M+ cloud devices (2024)
- Financial context: ~$4.8B FY2024 revenue
- APIs: clinician workflows, patient self-management
- Outcomes: enhanced data-driven care pathways
Partnerships drive adherence, consumables ~35%, 15M devices
Key partnerships with hospitals, DMEs, payers, suppliers and telehealth platforms enable referrals, last‑mile setup, reimbursement access, component supply and remote care integration; ResMed reported ~$4.8B FY2024 revenue and ~15M cloud‑enabled devices in 2024. These alliances drive adherence, recurring consumables (~35% of sales) and value‑based contracts that lower hospitalizations.
| Partner | Role | 2024 metric |
|---|---|---|
| Hospitals/Clinics | Referrals, protocols | 15M cloud devices |
| DMEs | Delivery, training, resupply | Consumables ~35% rev |
| Payers | Coverage, value contracts | ↓ hospitalizations up to 30% |
| Suppliers | Motors, sensors | Supply stability for $4.8B rev |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for ResMed outlining nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure—reflecting its connected sleep and respiratory care strategy, competitive strengths, risks, and investor-ready insights.
Customizable Excel Spreadsheet
Condenses ResMed’s business model into a one-page snapshot showing how its connected CPAP devices, cloud-based monitoring and integrated services relieve clinical and operational pain points—improving patient adherence, reducing hospital readmissions and lowering provider workload. Shareable and editable for team collaboration or quick executive summaries.
Activities
Medical device R&D
ResMed’s medical device R&D designs and tests CPAPs, masks, ventilators and diagnostics, iterating on materials and airflow for comfort and noise reduction to boost adherence. R&D emphasizes smart features—remote monitoring and algorithmic therapy adjustments—to raise nightly use rates. Clinical studies in 2024 continued to validate safety and efficacy, supporting regulatory approvals; ResMed invested about $383 million in R&D in FY2024.
Regulatory and quality management
ResMed maintains compliance with FDA, CE and global standards across 140+ countries, underpinning a FY2024 revenue base of roughly $4.6B. Robust post-market surveillance and CAPA processes track safety signals and drive corrective actions. Comprehensive documentation and traceability support audits, regulatory submissions and market access decisions worldwide.
Manufacturing and supply chain
Scale production with strict quality controls to support ResMed’s global footprint after FY2024 revenue of $4.92 billion. Manufacturing relies on multi-sourced components and inventory buffering to maintain device availability across more than 120 countries. Logistics networks are optimized for rapid global distribution and service-level targets. Continuous quality audits sustain regulatory compliance and yield targets.
Cloud software development
ResMed's cloud software development builds remote monitoring, analytics and patient apps—supporting over 11 million connected devices and contributing to FY2024 revenue of $4.6B; it enforces security, privacy and FHIR interoperability; delivers OTA updates that boost adherence and cut clinic workflow time by ~20%.
- Remote monitoring: real-time telemetry
- Security: HIPAA, FHIR-compatible
- Updates: higher adherence, -20% clinic time
Commercial and clinical education
- Train clinicians, DMEs, patients on setup/best practices
- Adherence programs & outreach to improve therapy use
- Reimbursement support & health-economic evidence
R&D $383M: CPAPs, masks, ventilators & cloud; ~11M devices, >20M patients
ResMed focuses R&D on CPAPs, masks, ventilators and cloud software, investing $383M in FY2024 to improve comfort, algorithms and remote monitoring for ~11M connected devices. Manufacturing and QA scale to supply >120 countries supporting FY2024 revenues of $4.92B. Clinical, reimbursement and adherence programs served >20M patients in 2024.
| Metric | 2024 |
|---|---|
| R&D spend | $383M |
| Connected devices | ~11M |
| Patients served | >20M |
| Revenue (FY) | $4.92B |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual ResMed Business Model Canvas you'll receive after purchase. It's not a mockup—it's the same editable, ready-to-use file, formatted for presentation and analysis in Word and Excel. Purchase unlocks the complete document with all content included—no surprises, ready to edit and share.
Original: $10.00
-65%$10.00
$3.50Description
Unlock the strategic Business Model Canvas for a leading sleep-tech innovator
Unlock the full strategic blueprint behind ResMed’s business model with our in-depth Business Model Canvas—three to five actionable sentences show how ResMed creates value, scales distribution, and monetizes clinical innovation. Ideal for investors, consultants, and founders, this downloadable Word/Excel file gives a section-by-section breakdown and ready-to-use slides for benchmarking or strategy work—purchase the full canvas to dive deeper.
Partnerships
Hospitals and sleep clinics
Clinical providers conduct diagnostics, prescribe therapy, and drive device adoption, linking hospital pathways to home care; obstructive sleep apnea affects an estimated 936 million adults worldwide. Partnerships ensure seamless patient referrals and titration workflows, reducing friction across care transitions. Co-development of protocols with hospitals and sleep clinics elevates clinical outcomes and adherence; ResMed supports over 8 million cloud-connected devices globally, enabling data-driven follow-up.
Durable medical equipment (DME) distributors
DME distributors manage last-mile delivery, device setup, and patient training for home sleep and ventilation, reducing onboarding times and readmissions. They handle mask and supplies replenishment, sustaining recurring consumables revenue—ResMed reported approximately $4.9B revenue in FY2024 with consumables/services ~35% of sales. Joint programs with DMEs raise adherence and tighten resupply cadence, improving lifetime customer value.
Payers and health systems
Payers and integrated delivery networks control CPAP and ventilator coverage, prior authorizations and reimbursement levels that shape ResMed market access. Value-based contracts increasingly tie payments to adherence and outcomes, with studies reporting up to 30% fewer hospitalizations when PAP therapy is optimized. Shared device and adherence data have supported cost-effectiveness evidence used in payer negotiations and formulary decisions.
Component suppliers and OEMs
- High-quality components
- Supply reliability & cost stability
- Co-innovation: quieter, smaller, efficient
Software and telehealth partners
- Integrations: EHRs, telemedicine, remote monitoring
- Scale: ~15M+ cloud devices (2024)
- Financial context: ~$4.8B FY2024 revenue
- APIs: clinician workflows, patient self-management
- Outcomes: enhanced data-driven care pathways
Partnerships drive adherence, consumables ~35%, 15M devices
Key partnerships with hospitals, DMEs, payers, suppliers and telehealth platforms enable referrals, last‑mile setup, reimbursement access, component supply and remote care integration; ResMed reported ~$4.8B FY2024 revenue and ~15M cloud‑enabled devices in 2024. These alliances drive adherence, recurring consumables (~35% of sales) and value‑based contracts that lower hospitalizations.
| Partner | Role | 2024 metric |
|---|---|---|
| Hospitals/Clinics | Referrals, protocols | 15M cloud devices |
| DMEs | Delivery, training, resupply | Consumables ~35% rev |
| Payers | Coverage, value contracts | ↓ hospitalizations up to 30% |
| Suppliers | Motors, sensors | Supply stability for $4.8B rev |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for ResMed outlining nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships, and cost structure—reflecting its connected sleep and respiratory care strategy, competitive strengths, risks, and investor-ready insights.
Customizable Excel Spreadsheet
Condenses ResMed’s business model into a one-page snapshot showing how its connected CPAP devices, cloud-based monitoring and integrated services relieve clinical and operational pain points—improving patient adherence, reducing hospital readmissions and lowering provider workload. Shareable and editable for team collaboration or quick executive summaries.
Activities
Medical device R&D
ResMed’s medical device R&D designs and tests CPAPs, masks, ventilators and diagnostics, iterating on materials and airflow for comfort and noise reduction to boost adherence. R&D emphasizes smart features—remote monitoring and algorithmic therapy adjustments—to raise nightly use rates. Clinical studies in 2024 continued to validate safety and efficacy, supporting regulatory approvals; ResMed invested about $383 million in R&D in FY2024.
Regulatory and quality management
ResMed maintains compliance with FDA, CE and global standards across 140+ countries, underpinning a FY2024 revenue base of roughly $4.6B. Robust post-market surveillance and CAPA processes track safety signals and drive corrective actions. Comprehensive documentation and traceability support audits, regulatory submissions and market access decisions worldwide.
Manufacturing and supply chain
Scale production with strict quality controls to support ResMed’s global footprint after FY2024 revenue of $4.92 billion. Manufacturing relies on multi-sourced components and inventory buffering to maintain device availability across more than 120 countries. Logistics networks are optimized for rapid global distribution and service-level targets. Continuous quality audits sustain regulatory compliance and yield targets.
Cloud software development
ResMed's cloud software development builds remote monitoring, analytics and patient apps—supporting over 11 million connected devices and contributing to FY2024 revenue of $4.6B; it enforces security, privacy and FHIR interoperability; delivers OTA updates that boost adherence and cut clinic workflow time by ~20%.
- Remote monitoring: real-time telemetry
- Security: HIPAA, FHIR-compatible
- Updates: higher adherence, -20% clinic time
Commercial and clinical education
- Train clinicians, DMEs, patients on setup/best practices
- Adherence programs & outreach to improve therapy use
- Reimbursement support & health-economic evidence
R&D $383M: CPAPs, masks, ventilators & cloud; ~11M devices, >20M patients
ResMed focuses R&D on CPAPs, masks, ventilators and cloud software, investing $383M in FY2024 to improve comfort, algorithms and remote monitoring for ~11M connected devices. Manufacturing and QA scale to supply >120 countries supporting FY2024 revenues of $4.92B. Clinical, reimbursement and adherence programs served >20M patients in 2024.
| Metric | 2024 |
|---|---|
| R&D spend | $383M |
| Connected devices | ~11M |
| Patients served | >20M |
| Revenue (FY) | $4.92B |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual ResMed Business Model Canvas you'll receive after purchase. It's not a mockup—it's the same editable, ready-to-use file, formatted for presentation and analysis in Word and Excel. Purchase unlocks the complete document with all content included—no surprises, ready to edit and share.
